Clinical Trials
369 trialsAnti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Janssen Research & Development, LLC
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma, Inc.
FiREBOLT
Eli Lilly and Company
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Bristol-Myers Squibb
OMNIRAY
Eli Lilly and Company
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
FOCUS-01
Avacta Life Sciences Ltd
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain
Case Comprehensive Cancer Center
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Dispatch Biotherapeutics
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
STELLAR-002
Exelixis
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
EMD Serono
NEXUS-01
Eli Lilly and Company
INVOKE
Epkin
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
Catherine
Vall d'Hebron Institute of Oncology
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PanTher Therapeutics
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
Dong-A ST Co., Ltd.
PIONEER
University of Utah
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono